Please use this identifier to cite or link to this item:
https://doi.org/10.1245/s10434-010-1038-8
DC Field | Value | |
---|---|---|
dc.title | Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker | |
dc.contributor.author | Chen, L. | |
dc.contributor.author | Ho, D.W.Y. | |
dc.contributor.author | Lee, N.P.Y. | |
dc.contributor.author | Sun, S. | |
dc.contributor.author | Lam, B. | |
dc.contributor.author | Wong, K.-F. | |
dc.contributor.author | Yi, X. | |
dc.contributor.author | Lau, G.K. | |
dc.contributor.author | Ng, E.W.Y. | |
dc.contributor.author | Poon, T.C.W. | |
dc.contributor.author | Lai, P.B.S. | |
dc.contributor.author | Cai, Z. | |
dc.contributor.author | Peng, J. | |
dc.contributor.author | Leng, X. | |
dc.contributor.author | Poon, R.T.P. | |
dc.contributor.author | Luk, J.M. | |
dc.date.accessioned | 2014-12-12T08:00:18Z | |
dc.date.available | 2014-12-12T08:00:18Z | |
dc.date.issued | 2010-09 | |
dc.identifier.citation | Chen, L., Ho, D.W.Y., Lee, N.P.Y., Sun, S., Lam, B., Wong, K.-F., Yi, X., Lau, G.K., Ng, E.W.Y., Poon, T.C.W., Lai, P.B.S., Cai, Z., Peng, J., Leng, X., Poon, R.T.P., Luk, J.M. (2010-09). Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Annals of Surgical Oncology 17 (9) : 2518-2525. ScholarBank@NUS Repository. https://doi.org/10.1245/s10434-010-1038-8 | |
dc.identifier.issn | 10689265 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/117005 | |
dc.description.abstract | Background: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. © 2010 Society of Surgical Oncology. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1245/s10434-010-1038-8 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.description.doi | 10.1245/s10434-010-1038-8 | |
dc.description.sourcetitle | Annals of Surgical Oncology | |
dc.description.volume | 17 | |
dc.description.issue | 9 | |
dc.description.page | 2518-2525 | |
dc.description.coden | ASONF | |
dc.identifier.isiut | 000281858600035 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.